However, as mentioned earlier, there is evidence that the tumor can become resistant to VEGF-targeted therapy and acquire resistance against monotherapy with VEGFR inhibitors that manipulate other angiogenesis mechanisms [156]. This evidence concerns the gene KDR and neoplasm.